Clover Health Investments Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Clover Health InvestmentsDie Umsatzerlöse des Unternehmens werden voraussichtlich um 3.2% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 11.6% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 12% pro Jahr wachsen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -23.6% betragen.

Wichtige Informationen

19.8%

Wachstumsrate der Gewinne

20.2%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	19.3%
Wachstumsrate der Einnahmen	-2.4%
Zukünftige Eigenkapitalrendite	-16.8%
Analystenabdeckung	Low
Zuletzt aktualisiert	13 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Clover Health: A Profitable Future Ahead Fueled By AI And Star Rating Success

Aug 15

Clover Health Investments, Corp. (NASDAQ:CLOV) Surges 32% Yet Its Low P/S Is No Reason For Excitement

Aug 14

Here's Why We're Watching Clover Health Investments' (NASDAQ:CLOV) Cash Burn Situation

Aug 06

Clover Health Investments, Corp.'s (NASDAQ:CLOV) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Jun 12

Clover Health Investments, Corp.'s (NASDAQ:CLOV) 26% Dip In Price Shows Sentiment Is Matching Revenues

Apr 20

Clover Health Investments, Corp. (NASDAQ:CLOV) Analysts Are Reducing Their Forecasts For This Year

Mar 16

Will Clover Health Investments (NASDAQ:CLOV) Spend Its Cash Wisely?

Mar 06

Clover Health: Its Luck May Have Ran Out

Feb 26

Here's Why We're Not Too Worried About Clover Health Investments' (NASDAQ:CLOV) Cash Burn Situation

Nov 21

We're Hopeful That Clover Health Investments (NASDAQ:CLOV) Will Use Its Cash Wisely

Jul 07

Clover Health to expand Medicare Advantage plans to 13 additional counties, exit 2

Jul 15

Is Clover Health A Good Healthcare Sector Stock Pick?

Jun 30

Clover Set To Report Earnings Tonight: Levels To Watch

May 09

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:CLOV - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,560	-54	N/A	N/A	2
12/31/2025	1,465	-61	N/A	N/A	3
12/31/2024	1,385	-67	N/A	N/A	3
6/30/2024	2,090	-121	-178	-177	N/A
3/31/2024	2,059	-157	-170	-169	N/A
12/31/2023	2,036	-213	-116	-116	N/A
9/30/2023	2,040	-234	-183	-178	N/A
6/30/2023	2,441	-268	-63	-58	N/A
3/31/2023	2,989	-344	-155	-150	N/A
12/31/2022	3,579	-340	-291	-286	N/A
9/30/2022	3,041	-443	-76	-75	N/A
6/30/2022	2,564	-402	-222	-222	N/A
3/31/2022	2,075	-615	-247	-246	N/A
12/31/2021	1,361	-588	-283	-282	N/A
9/30/2021	1,158	-527	-263	-262	N/A
6/30/2021	922	-487	-252	-252	N/A
3/31/2021	721	-160	-175	-174	N/A
12/31/2020	690	-136	-119	-118	N/A
9/30/2020	624	-89	-126	-126	N/A
6/30/2020	572	-145	-116	-116	N/A
3/31/2020	507	-272	-163	-163	N/A
12/31/2019	455	-364	-160	-160	N/A
12/31/2018	281	-202	-155	-153	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CLOV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CLOV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CLOV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CLOVDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-3.2% pro Jahr).

Hohe Wachstumseinnahmen: CLOVDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-3.2% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CLOV wird voraussichtlich in 3 Jahren unrentabel sein.

Clover Health Investments Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 17%

Clover Health Investments, Corp. Updates Earnings Guidance for the Full Year 2023

Clover Health Investments, Corp. Updates Earnings Guidance for the Full Year 2023

Price target decreased by 23% to US$1.50

Consensus EPS estimates upgraded to US$0.55 loss

Price target increased by 7.4% to US$1.57

Recent updates

New major risk - Share price stability

Clover Health Investments, Corp. Appoints Thomas L. Tran to Its Board of Directors and Member of the Audit Committee

Clover Health: A Profitable Future Ahead Fueled By AI And Star Rating Success

Co-Founder & Executive Chairman recently bought US$1m worth of stock

Clover Health Investments, Corp. (NASDAQ:CLOV) Surges 32% Yet Its Low P/S Is No Reason For Excitement

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Watching Clover Health Investments' (NASDAQ:CLOV) Cash Burn Situation

Clover Health Investments, Corp. to Report Q2, 2024 Results on Aug 05, 2024

Co-Founder & Executive Chairman recently bought US$1.0m worth of stock

Clover Health Investments, Corp.'s (NASDAQ:CLOV) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Clover Health Investments, Corp. Announces Counterpart Health, A New SaaS and Tech Enabled Services Solution to Bring the Power of CA Technology to All Medicare Advantage Payors and Providers

Clover Health Investments, Corp. (NasdaqGS:CLOV) announces an Equity Buyback for $20 million worth of its shares.

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Clover Health Investments, Corp., Annual General Meeting, Jun 10, 2024

Clover Health Investments, Corp. to Report Q1, 2024 Results on May 07, 2024

Clover Health Investments, Corp. Announces the Appointment of Peter Kuipers as Chief Financial Officer

Clover Health Investments, Corp.'s (NASDAQ:CLOV) 26% Dip In Price Shows Sentiment Is Matching Revenues

Clover Health Investments Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 17%

Independent Director recently bought US$110k worth of stock

Clover Health Investments, Corp. (NASDAQ:CLOV) Analysts Are Reducing Their Forecasts For This Year

New minor risk - Shareholder dilution

Clover Health Investments, Corp. Reports Impairment of Goodwill and Other Intangible Assets for the Fourth Quarter Ended December 31, 2023

Clay Thornton Joins Clover Health as CFO of Medicare Advantage Division

Will Clover Health Investments (NASDAQ:CLOV) Spend Its Cash Wisely?

Clover Health Investments, Corp. to Report Q4, 2023 Results on Mar 12, 2024

Clover Health: Its Luck May Have Ran Out

Co-Founder & Executive Chairman exercised options and sold US$1.5m worth of stock

Clover Health Investments, Corp. Announces Management Changes

Clover Health Investments, Corp. Announces Resignation of Scott J. Leffler as Chief Financial Officer, Effective January 26, 2024

Here's Why We're Not Too Worried About Clover Health Investments' (NASDAQ:CLOV) Cash Burn Situation

New minor risk - Shareholder dilution

Clover Health Investments, Corp. Updates Earnings Guidance for the Full Year 2023

Clover Health Investments, Corp. Updates Earnings Guidance for the Full Year 2023

Price target decreased by 23% to US$1.50

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Clover Health Promotes Karen Soares to General Counsel

Clover Health Investments, Corp. to Report Q3, 2023 Results on Nov 06, 2023

Consensus EPS estimates upgraded to US$0.55 loss

Price target increased by 7.4% to US$1.57

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Clover Health Investments, Corp. Provides Earnings Guidance for the Year 2023

Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement

Clover Health Investments, Corp. to Report Q2, 2023 Results on Aug 08, 2023

We're Hopeful That Clover Health Investments (NASDAQ:CLOV) Will Use Its Cash Wisely

Clover Health Investments, Corp. Announces Agreement to Settle Derivative Litigation, Resolving All Remaining Civil Litigation Relating to its de-SPAC Transaction

New minor risk - Share price stability

Clover Health Investments, Corp. Announces the Resignation of Joseph Martin as General Counsel and Corporate Secretary

Price target decreased by 12% to US$1.46

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.16 loss in 1Q 2022)

Clover Health Investments, Corp. Provides Revenue Guidance for the Full Year 2023

Consensus revenue estimates fall by 10%

Price target decreased by 11% to US$1.83

Full year 2022 earnings released: US$0.71 loss per share (vs US$1.42 loss in FY 2021)

Clover Health Investments, Corp., Annual General Meeting, Feb 07, 2023

Clover Health Investments, Corp. to Report Q4, 2022 Results on Feb 28, 2023

Clover Health Investments, Corp. Announces Stepdown of Prabhdeep Singh as Chief Growth Officer, Effective March 31, 2023

Clover Health Investments, Corp. Appoints Jamie L. Reynoso as Chief Executive Officer of Medicare Advantage

High number of new directors

Clover Health Investments, Corp. Announces the Appointment of Anna Loengard, M.D. to the Company’s Board of Directors

Consensus estimates of losses per share improve by 13%

Price target decreased to US$2.63

Price target decreased to US$3.08

Third quarter 2022 earnings: Revenues exceed analyst expectations

Clover Health Investments, Corp. Provides Earnings Guidance for the Year 2022

Chamath Palihapitiya-linked Clover Health Investments trading near all-time low

Clover Health Investments, Corp. to Report Q3, 2022 Results on Nov 07, 2022

Insider recently sold US$20m worth of stock

Chamath Palihapitiya cuts stake in Clover Health to under 5%